摘要
缺氧是由于肿瘤细胞生长速度快、血液供应不足而在肿瘤环境中经常出现的一种情况。越来越多的证据表明,缺氧在癌症休眠和癌症代谢中发挥重要作用,增加干活动并引起癌症的发生和发展。 这种情况可能影响缺氧诱导因子(HIF)的产生,螺旋转录因子通过调节参与血管生成,糖酵解代谢和其他生物机制的基因参与癌发生和肿瘤生长。在常氧条件下,使用氧作为底物,HIF被脯氨酰羟化酶(EGLN 1-3,也称为PHD 1-3)灭活。一旦水解,它就会结合一种名为Von Hippel Lindau蛋白(VHL)的蛋白质进行降解,而在缺氧条件下会发生稳定化和核转位,从而导致癌基因活化。它有三种异构体HIF-1 HIF-2和HIF-3。研究最多的因子是HIF-1,它是由两种形式组成的异二聚体,形式α以氧依赖的方式表达,β形式是组成型表达的。 其在肿瘤微环境中的存在可以促进VEGF,HGF,Met质子基因的表达,其诱导细胞外基质和TWIST基因的降解,其反过来涉及称为上皮 - 间充质转换(EMT)的癌细胞转移机制。在这篇综述中,我们总结了不同类型癌症中HIF作用的最重要发现,重点是其诱导肿瘤细胞生长的特性,并突出其在不同癌症部位的不良预后价值。
关键词: HIF-1,转移,肿瘤进展,缺氧,微环境,代谢途径。
Current Molecular Medicine
Title:Role of HIF-1 in Cancer Progression: Novel Insights. A Review
Volume: 18 Issue: 6
关键词: HIF-1,转移,肿瘤进展,缺氧,微环境,代谢途径。
摘要: Hypoxia is a condition always present in tumor environment owing to the fast growth of tumor cells not supported by adequate blood supply.
There is increasing evidence that hypoxia plays an important role in cancer dormancy and cancer metabolism, increasing stemness activity and bringing about cancer initiation and progression.
This condition may influence the production of hypoxia inducible factor (HIF) a helix transcription factor which is involved in carcinogenesis and tumor growth through the regulation of genes involved in angiogenesis, glycolytic metabolism and other biological mechanisms.
In normoxia condition HIF is inactivated by prolyl hydroxylase enzymes (EGLN 1–3, also known as PHD 1–3) using oxygen as a substrate. Once hydroxilated it binds to a protein called Von Hippel Lindau protein (VHL) for its degradation, whereas in hypoxia condition stabilization and nuclear translocation occur, leading to oncogenes activation. It has got three isoforms HIF-1 HIF-2 and HIF-3. The most studied factor is HIF-1 which is a heterodimer consisting of two forms, the form α is expressed in manner oxygen dependent, the form β is expressed constitutively.
Its presence in tumor microenvironment could foster among other the expression of VEGF, HGF, Met protoncogene which induces degradation of the extracellular matrix and TWIST gene, which is in turn involved in a mechanism of cancer cell metastasis called epithelial-mesenchimal transition(EMT). In this review, we summarize the most important findings in HIF action in different types of cancer focusing on its properties to induce tumor cell growth and highlighting its poor prognostic value in different cancers sites.
Export Options
About this article
Cite this article as:
Role of HIF-1 in Cancer Progression: Novel Insights. A Review, Current Molecular Medicine 2018; 18 (6) . https://dx.doi.org/10.2174/1566524018666181109121849
DOI https://dx.doi.org/10.2174/1566524018666181109121849 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells
Current Cancer Drug Targets Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Patent Selections
Recent Patents on Biotechnology NFκB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities
Current Medicinal Chemistry BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Communicating Vaccine Safety in the Context of Immunization Programs in Low Resource Settings
Current Drug Safety Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents Preparation, Characterization and in vivo Evaluation of Raloxifene Hydrochloride Solid Lipid Nanoparticles
Pharmaceutical Nanotechnology Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
Current Pharmaceutical Biotechnology Synthesis and Single-Crystal X-Ray Diffraction Studies of an Arylidenethiosemicarbazone and Hydrazonyl-phenylthiazole
Letters in Organic Chemistry Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Liposomal Formulation of Monovalent Cholesteryl Cytofectins with Acyclic Head Groups and Gene Delivery: A Systematic Review
Current Pharmaceutical Biotechnology Development of Method for Three-Point Data Estimation and SVR-QSAR Model to Screen Anti Cancer Leads
Combinatorial Chemistry & High Throughput Screening Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Editorial [Hot Topic: How Drugs may Work to Better Protect the Gastrointestinal Tract: Mechanisms Involved in Gastrointestinal Tract Protection]
Current Pharmaceutical Design Editorial (Thematic Issue: Study and Prediction of Pharmacokinetic Drug-Drug Interactions)
Current Drug Metabolism